EGFR and non-small cell lung carcinoma: To date, there is no direct evidence on first‐line immunotherapy for advanced NSCLC with EGFR ex20ins, even though the post‐analysis of IMpower150 study has indicated clinical benefit of ICI combined with chemotherapy and bevacizumab for this subset of patients.20